Clinical Practice Guidelines and Consensus Statements in Oncology – An Assessment of Their Methodological Quality

Carmel Jacobs1*, Ian D. Graham2,3, Julie Makarski4, Michaël Chassé2, Dean Fergusson2,3, Brian Hutton2, Mark Clemons1,3

1 Division of Medical Oncology, The Ottawa Hospital Cancer Centre and Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada, 2 Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada, 3 Ottawa Hospital Research Institute and University of Ottawa, Department of Medicine, Ottawa, Ontario, Canada, 4 Independent Consultant, Hamilton, Ontario, Canada

Abstract

Background: Consensus statements and clinical practice guidelines are widely available for enhancing the care of cancer patients. Despite subtle differences in their definition and purpose, these terms are often used interchangeably. We systematically assessed the methodological quality of consensus statements and clinical practice guidelines published in three commonly read, geographically diverse, cancer-specific journals. Methods Consensus statements and clinical practice guidelines published between January 2005 and September 2013 in Current Oncology, European Journal of Cancer and Journal of Clinical Oncology were evaluated. Each publication was assessed using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) rigour of development and editorial independence domains. For assessment of transparency of document development, 7 additional items were taken from the Institute of Medicine’s standards for practice guidelines and the Journal of Clinical Oncology guidelines for authors of guidance documents.

Methods: Consensus statements and clinical practice guidelines published between January 2005 and September 2013 in Current Oncology, European Journal of Cancer and Journal of Clinical Oncology were evaluated. Each publication was assessed using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) rigour of development and editorial independence domains. For assessment of transparency of document development, 7 additional items were taken from the Institute of Medicine’s standards for practice guidelines and the Journal of Clinical Oncology guidelines for authors of guidance documents.

Findings: Thirty-four consensus statements and 67 clinical practice guidelines were evaluated. The rigour of development score for consensus statements over the three journals was 32% lower than that of clinical practice guidelines. The editorial independence score was 15% lower for consensus statements than clinical practice guidelines. One journal scored consistently lower than the others over both domains. No journals adhered to all the items related to the transparency of document development. One journal’s consensus statements endorsed a product made by the sponsoring pharmaceutical company in 64% of cases.

Conclusion: Guidance documents are an essential part of oncology care and should be subjected to a rigorous and validated development process. Consensus statements had lower methodological quality than clinical practice guidelines using AGREE II. At a minimum, journals should ensure that that all consensus statements and clinical practice guidelines adhere to AGREE II criteria. Journals should consider explicitly requiring guidelines to declare pharmaceutical company sponsorship and to identify the sponsor’s product to enhance transparency.

Citation: Jacobs C, Graham ID, Makarski J, Chassé M, Fergusson D, et al. (2014) Clinical Practice Guidelines and Consensus Statements in Oncology – An Assessment of Their Methodological Quality. PLoS ONE 9(10): e110469. doi:10.1371/journal.pone.0110469

Editor: Eugenio Paci, ISPO, Italy

Received June 20, 2014; Accepted September 22, 2014; Published October 17, 2014

Copyright: © 2014 Jacobs et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper.

Funding: IG received funding from the Canadian Institutes of Health Research (CIHR) number; FRN:IOP 123548 (http://www.cihr-irsc.gc.ca/e/193.html). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: Ian Graham was a member of the team that developed the AGREE II instrument. He has also been an author on practice guidelines from Cancer Care Ontario (CCO). He was not an author on any of the guidelines analysed in this manuscript. Brian Hutton has previously received funds for providing methodological advice to Amgen Canada for systematic reviews. Mark Clemons has previously been involved in the creation of practice guidelines for Cancer Care Ontario (CCO) and consensus statements for Roche; he was not an author on any of the guidelines analysed. No other authors have competing interests to declare. This does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.

* Email: cjacobs@toh.on.ca
Introduction

Consensus statements and clinical practice guidelines are widely used in oncology to improve the quality of patient care [1,2]. While both consensus statements and clinical practice guidelines are intended to provide guidance to clinicians, there are important differences between them. A clinical practice guideline (also called a medical guideline or clinical protocol) produces statements that are informed by a systematic review of the evidence and an assessment of the benefits and harms of alternative options [3]. A consensus statement is developed by an independent panel of experts, usually multidisciplinary, convened to review the research literature in an evidence-based manner for the purpose of advancing the understanding of an issue, procedure or method.
Both documents provide recommendations for optimizing patient care [3]. Although consensus statements address topics in which the evidence base is less extensive compared to clinical practice guidelines, their development should still be methodologically rigorous and transparent [4]. To assist with maintaining methodological rigor, organizations such as Appraisal of Guidelines for Research and Evaluation (AGREE) [5], Institute of Medicine (IOM) [3] and Guidelines International Network (GIN) [6] have developed criteria to ensure objective, scientifically valid, and consistent standards for the development and reporting of high quality guidance documents.

Given their widespread availability and importance for both clinical practice and funding decisions [7], we sought to evaluate the methodological quality of both consensus statements and clinical practice guidelines published in three commonly accessed oncology-specific journals through the domains of rigor of development and editorial independence. Information around the transparency of document development was also collected to assess whether or not pharmaceutical company sponsored guidelines were more likely to endorse a product manufactured by the sponsoring company.

**Methods**

Three oncology specific journals were searched for consensus statements and clinical practice guidelines published from January 2005–September 2013. Current Oncology (CO), the European Journal of Cancer (EJC) and the Journal of Clinical Oncology (JCO) were chosen as they have editorial offices in different countries.

| Table 2. AGREE II: Rigour of development and Editorial Independence. |
|---------------------------------------------------------------|
| **AGREE II: Rigour of development (Domain 3)**                                        |
| Consensus Statement (n = 34)                                      |
| Mean (95% Confidence Interval)                                   |
| 31 (21, 42) 36 (28, 45) 30 (19, 41) 32 (27, 38)                  |
| Clinical Practice Guideline (n = 67)                             |
| Mean (95% Confidence Interval)                                   |
| 70 (61, 79) 46 (32, 60) 68 (64, 72) 64 (59, 69)                  |
| Mean difference Consensus Statement vs Clinical Practice Guideline |
| 32 (24, 40)                                                      |
| Overall p-value Consensus Statement vs Clinical Practice Guideline |
| <0.0001                                                          |

| **AGREE II: Editorial Independence (Domain 6)**                                        |
| Consensus Statement (n = 34)                                      |
| Mean (95% Confidence Interval)                                   |
| 50 (38, 62) 44 (34, 54) 63 (56, 70) 53 (47, 59)                  |
| Clinical Practice Guideline (n = 67)                             |
| Mean (95% Confidence Interval)                                   |
| 75 (63, 86) 59 (52, 67) 66 (61, 70) 68 (63, 73)                  |
| Mean difference Consensus Statement vs Clinical Practice Guideline |
| 15 (7, 23)                                                       |
| Overall p-value Consensus Statement vs Clinical Practice Guideline |
| 0.0003                                                           |

Figure 2. Range and 95% confidence intervals for Editorial independence scores. CO = Current Oncology. EJC = European Journal of Cancer. CS = Consensus statements. JCO = Journal of Clinical Oncology. CPG = Clinical practice guidelines. doi:10.1371/journal.pone.0110469.g002
countries and for their perceived prominence in North America and Europe. January 2005 was chosen as the starting date for eligibility, as this was the date by which all three journals had accessible electronic archives. Each journal’s online search tool was used to search for the terms “consensus”, “consensus guideline”, “consensus statement”, “clinical practice guideline”, “practice guideline” or “medical guideline” in the title. Two reviewers (CJ, MC) reviewed each document retrieved to ensure they were consensus statements or practice guidelines, using the IOM criteria “statements that include recommendations intended to optimize patient care” [3].

As our primary focus related to evaluating the methodological quality, we opted to use Domain 3 of the AGREE II tool (Rigour of Development) and Domain 6 (Editorial Independence) to assess the documents. The rigour of development domain consists of 8 items, while the editorial independence domain consists of 2 items (items are shown in Table 1). AGREE II items are scored on a 7-point Likert scale ranging from 1 (strongly disagree) to 7 (strongly agree).

### Table 3. Additional items addressing Transparency of Document Development.

|                                         | CO n (%) | EJC n (%) | JCO n (%) | Overall n (%) | p-value   |
|----------------------------------------|----------|-----------|-----------|---------------|-----------|
| **Systematic review performed**        |          |           |           |               |           |
| Consensus Statement yes (n=34)        | 3 (21)   | 3 (33)    | 0         | 6 (18)        | 0.1350    |
| Clinical Practice Guideline yes (n=67)| 21 (88)  | 7 (54)    | 28 (93)   | 56 (84)       | 0.0082    |
| Overall Consensus Statement vs Clinical Practice Guideline difference |          |           |           |               | <0.0001   |
| **How groups were established**       |          |           |           |               |           |
| Consensus Statement (n=34)             |          |           |           |               |           |
| Invited                                | 6 (43)   | 5 (56)    | 1 (9)     | 12 (35)       | 0.1440    |
| Not reported                           | 6 (43)   | 4 (44)    | 7 (64)    | 17 (50)       |           |
| Other                                  | 2 (14)   | 0         | 3 (27)    | 5 (15)        |           |
| Clinical Practice Guideline (n=67)     |          |           |           |               |           |
| Invited                                | 4 (17)   | 5 (39)    | 5 (17)    | 14 (21)       | 0.0378    |
| Not reported                           | 7 (29)   | 7 (54)    | 9 (30)    | 23 (34)       |           |
| Other                                  | 13 (54)  | 1 (8)     | 16 (53)   | 30 (45)       |           |
| Overall Consensus Statement vs Clinical Practice Guideline difference |          |           |           |               | 0.0106    |
| **Multidisciplinary**                  |          |           |           |               |           |
| Consensus Statement (n=34)             |          |           |           |               |           |
| Yes                                    | 8 (57)   | 7 (78)    | 6 (55)    | 21 (62)       | 0.7282    |
| No                                     | 1 (7)    | 0         | 0         | 1 (3)         |           |
| Not reported                           | 5 (36)   | 2 (22)    | 5 (46)    | 12 (35)       |           |
| Clinical Practice Guideline (n=67)     |          |           |           |               |           |
| Yes                                    | 19 (79)  | 8 (62)    | 23 (77)   | 50 (75)       | 0.4716    |
| No                                     | 0         | 0         | 0         | 0             |           |
| Not reported                           | 5 (21)   | 5 (39)    | 7 (23)    | 17 (25)       |           |
| Overall Consensus Statement vs Clinical Practice Guideline difference |          |           |           |               | 0.1857    |
| **Privately funded meeting**           |          |           |           |               |           |
| Consensus Statement (n=34)             |          |           |           |               |           |
| Yes                                    | 9 (64)   | 2 (22)    | 0         | 11 (32)       | <0.0001   |
| No                                     | 1 (7)    | 0         | 0         | 1 (3)         |           |
| Not reported                           | 4 (29)   | 7 (78)    | 11 (100)  | 22 (65)       |           |
| Clinical Practice Guideline (n=67)     |          |           |           |               |           |
| Yes                                    | 1 (4)    | 5 (39)    | 0         | 6 (9)         | <0.0001   |
| No                                     | 15 (63)  | 0         | 16 (53)   | 31 (47)       |           |
| Not reported                           | 8 (33)   | 8 (62)    | 14 (47)   | 30 (45)       |           |
| Overall Consensus Statement vs Clinical Practice Guideline difference |          |           |           |               | <0.0001   |
| **Consensus sponsors’ product endorsed** |          |           |           |               |           |
| Consensus Statement (n=34)             |          |           |           |               |           |
| Yes                                    | 9 (64)   | 1 (11)    | 0         | 10 (24.4)     | <0.0001   |
| Clinical Practice Guideline (n=67)     |          |           |           |               |           |
| Yes                                    | 1 (4)    | 1 (8)     | 0         | 2 (3)         | 0.3012    |
| Overall Consensus Statement vs Clinical Practice Guideline difference |          |           |           |               | <0.0001   |

doi:10.1371/journal.pone.0110469.t003
### Table 4. Current Oncology Consensus Statements and Clinical Practice Guidelines.

| Paper                                                                 | Year published | Pharma sponsored | AGREE Domain 3 (%) | AGREE Domain 6 (%) | Sponsors product endorsed |
|----------------------------------------------------------------------|----------------|------------------|--------------------|--------------------|--------------------------|
| Recommendations of the Canadian Consensus Group on the Management of Chronic Myeloid Leukemia [12] | 2006           | ✓                | 50                 | 50                 | ✓                        |
| Updated recommendations from the Canadian National consensus meeting on HER2/neu testing in breast cancer [13] | 2007           | ✓                | 7                  | 17                 | ✓                        |
| Colorectal Cancer Association of Canada Consensus Meeting on Practice Guidelines - Raising the Standard of Care in Canada for Early Stage Rectal Cancer [14] | 2009           | ✓                | 22                 | 64                 | ✓                        |
| The role of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as Therapy for Advanced, Metastatic and Recurrent Non-Small Cell Lung Cancer: A Canadian National Consensus Statement [15] | 2009           | ✓                | 67                 | 46                 | ✓                        |
| Consensus recommendations for the use of anti-EGFR therapies in metastatic colorectal cancer [16] | 2010           | 6                | 54                 |                    |                          |
| Eastern Canadian Colorectal Cancer Consensus Conference: setting the limits of resectable disease [17] | 2010           | ✓                | 32                 | 21                 | ✓                        |
| Consensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuroendocrine tumours: a revised statement from a Canadian national expert group [18] | 2010           | ✓                | 23                 | 79                 | ✓                        |
| Diagnosis and management of hepatocellular carcinoma: results of a consensus meeting of The Ottawa Hospital Cancer Centre [19] | 2010           | ✓                | 33                 | 25                 | ✓                        |
| **Consensus Statements pre IOM 2011 (n = 8), Mean (95% Confidence Interval)** |                |                  |                    |                    |                          |
| Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma [20] | 2011           | ✓                | 56                 | 75                 | ✓                        |
| Canadian Expert Group consensus recommendations: KRAS testing in colorectal cancer [21] | 2011           | 19               | 58                 |                    |                          |
| Report from the 13th Annual Western Canadian Gastrointestinal Cancer Consensus Conference [22] | 2012           | 43               | 46                 |                    |                          |
| Consensus recommendations for cancer rehabilitation: research and education priorities [23] | 2013           | 14               | 79                 |                    |                          |
| Endocrine therapy for postmenopausal women with hormone receptor-positive her2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statement [24] | 2013           | ✓                | 40                 | 63                 | ✓                        |
| Eastern Canadian Colorectal Cancer Consensus Conference: standards of care for the treatment of patients with rectal, pancreatic, and gastrointestinal stomal tumours and pancreatic neuroendocrine tumours [25] | 2013           | 29               | 33                 |                    |                          |
| **Consensus Statements post IOM 2011 (n = 6), Mean (95% Confidence Interval)** |                |                  |                    |                    |                          |
| Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma [20] | 2011           | ✓                | 56                 | 75                 | ✓                        |
| Canadian Expert Group consensus recommendations: KRAS testing in colorectal cancer [21] | 2011           | 19               | 58                 |                    |                          |
| Report from the 13th Annual Western Canadian Gastrointestinal Cancer Consensus Conference [22] | 2012           | 43               | 46                 |                    |                          |
| Consensus recommendations for cancer rehabilitation: research and education priorities [23] | 2013           | 14               | 79                 |                    |                          |
| Endocrine therapy for postmenopausal women with hormone receptor-positive her2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statement [24] | 2013           | ✓                | 40                 | 63                 | ✓                        |
| Eastern Canadian Colorectal Cancer Consensus Conference: standards of care for the treatment of patients with rectal, pancreatic, and gastrointestinal stomal tumours and pancreatic neuroendocrine tumours [25] | 2013           | 29               | 33                 |                    |                          |
| Paper                                                                 | Year published | Pharma sponsored | AGREE Domain 3 (%) | AGREE Domain 6 (%) | Sponsors product endorsed |
|----------------------------------------------------------------------|----------------|------------------|--------------------|--------------------|--------------------------|
| **Clinical Practice Guidelines**                                      |                |                  |                    |                    |                          |
| Bortezomib in Multiple Myeloma and Lymphoma: A systematic review and clinical practice guideline [26] | 2006           | 82               | 88                 |                   |                          |
| Guidelines for the diagnosis and management of carcinoid tumours, part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group [27] | 2006           | 20               | 13                 |                   |                          |
| The role of oxaliplatin combined with 5-fluorouracil and folinic acid in the first- and second-line treatment of advanced colorectal cancer: a systematic review and clinical practice guideline [28] | 2006           | 74               | 21                 |                   |                          |
| Canadian Recommendations for the Treatment of Glioblastoma Multiforme [29] | 2007           | ✓                | 19                 | 17                 | ✓                        |
| Melanoma Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care Mot. Temozolomide for the Treatment of Metastatic Melanoma: A Practice Guideline [30] | 2007           | 80               | 92                 |                   |                          |
| Ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma: a systematic review and clinical practice guideline [31] | 2007           | 61               | 96                 |                   |                          |
| Management of Single Brain Metastases: A Practice Guideline [32]      | 2007           | 79               | 92                 |                   |                          |
| Alemtuzumab in Chronic Lymphocytic Leukemia: A Systematic Review and Clinical Practice Guideline [33] | 2007           | 81               | 100                |                   |                          |
| Single-Agent Interleukin-2 in the Treatment of Metastatic Melanoma: A Clinical Practice Guideline [34] | 2007           | 78               | 100                |                   |                          |
| Biochemotherapy for the Treatment of Metastatic Malignant Melanoma: A Clinical Practice Guideline [35] | 2008           | 43               | 75                 |                   |                          |
| Dose-intensive Chemotherapy with Growth Factor or Autologous Bone Marrow/Stem Cell Transplant Support in First-line Treatment of Advanced or Metastatic Adult Soft Tissue Sarcoma – A Clinical Practice Guideline [36] | 2008           | 89               | 100                |                   |                          |
| Epidermal growth factor receptor targeted therapy in stage III and IV head and neck cancer [37] | 2010           | 85               | 79                 |                   |                          |
| Follow-up for women after treatment for cervical cancer [38]          | 2010           | 78               | 79                 |                   |                          |
| **Clinical Practice Guidelines pre IOM 2011 (n = 13) Mean (95% Confidence Interval)** |                |                  |                    |                    |                          |
| Canadian College of Medical Geneticists guidelines for the indications, analysis, and reporting of cancer specimens [39] | 2011           | 18               | 46                 |                   |                          |
| Systemic therapy for advanced gastric cancer: a clinical practice guideline [40] | 2011           | 84               | 83                 |                   |                          |
| Paper                                                                 | Year published | Pharma sponsored | AGREE Domain 3 (%) | AGREE Domain 6 (%) | Sponsors product endorsed |
|----------------------------------------------------------------------|----------------|------------------|--------------------|--------------------|--------------------------|
| Survivorship services for adult cancer populations: a pan-Canadian guideline [41] | 2011           | 84               | 96                 |                    |                          |
| Invasive mediastinal staging of non-small-cell lung cancer: a clinical practice guideline [42] | 2011           | 75               | 83                 |                    |                          |
| Management of a suspicious adnexal mass: a clinical practice guideline [43] | 2012           | 80               | 63                 |                    |                          |
| Lenalidomide in multiple myeloma – a practice guideline [44]         | 2013           | 75               | 83                 |                    |                          |
| Chemotherapy (gemcitabine, docetaxel plus gemcitabine, doxorubicin, or trabectedin) in inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma: a clinical practice guideline [45] | 2013           | 82               | 88                 |                    |                          |
| Role of endolaryngeal surgery (with or without laser) compared with radiotherapy in the management of early T1 glottic cancer: a clinical practice guideline [46] | 2013           | 74               | 79                 |                    |                          |
| Surgical margins and handling of soft-tissue sarcoma in extremities: a clinical practice guideline [47] | 2013           | 77               | 100                |                    |                          |
| Liver resection for colorectal cancer metastases [48]                | 2013           | 80               | 83                 |                    |                          |
| A pan-Canadian practice guideline and algorithm: screening, assessment, and supportive care of adults with cancer-related fatigue [49] | 2013           | 75               | 38                 |                    |                          |

**Clinical Practice Guidelines post IOM 2011 (n = 11) Mean (95% Confidence Interval)**

73 (62, 84) 77 (65, 88)

doi:10.1371/journal.pone.0110469.t004
| Paper                                                                 | Year published | Pharma sponsored | AGREE Domain 3 | AGREE Domain 6 | Sponsors product endorsed |
|----------------------------------------------------------------------|----------------|------------------|---------------|---------------|--------------------------|
| EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome [50] | 2006 | 43 | 50 | | |
| Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. [51] | 2006 | 41 | 38 | | |
| Consensus conference: Implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice – Report of a European workshop [52] | 2008 | ✓ | 27 | 42 | ✓ |
| Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline [53] | 2010 | 39 | 38 | | |
| Breast cancer in pregnancy: Recommendations of an international consensus meeting. [54] | 2010 | 49 | 21 | | |
| **Consensus Statements pre IOM 2011 (n = 8), Mean (95% Confidence Interval)** | | | | | |
| Consensus on Lung Cancer, new clinical recommendations and current status of biomarker assessment – First-line therapy. [55] | 2011 | 15 | 38 | | |
| Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer – Differential treatment strategies for subtypes of early gastroesophageal cancer. [56] | 2012 | ✓ | 28 | 63 | |
| Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2012 [57] | 2012 | 35 | 63 | | |
| German, Austrian and Swiss consensus conference on the diagnosis and local treatment of the axilla in breast cancer [58] | 2013 | 50 | 46 | | |
| **Consensus Statements post IOM 2011 (n = 4), Mean (95% Confidence Interval)** | | | | | |
| Guidelines for surgical treatment of hepatoblastoma in the modern era–recommendations from the Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPEL) [59] | 2005 | 21 | 46 | | |
| Malignant ascites: systematic review and guideline for treatment. [60] | 2006 | 63 | 46 | | |
| EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. [61] | 2006 | ✓ | 72 | 50 | |
| EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update [62] | 2007 | ✓ | 60 | 88 | |
| Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use [63] | 2007 | 38 | 64 | | |
| Guidelines on the standards for the training of specialised health professionals dealing with breast cancer [64] | 2007 | ✓ | 0 | 46 | |
| Guidelines for the assessment of oral mucositis in adult chemotherapy, radiotherapy and haematopoietic stem cell transplant patients. European journal of cancer [65] | 2008 | 69 | 58 | | |
| Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: Guidelines of the infectious diseases working party of the German Society of Haematology and Oncology. [66] | 2009 | 18 | 58 | | |
| The development of evidence-based guidelines on mouth care for children, teenagers and young adults treated for cancer [67] | 2010 | 76 | 63 | | |
| 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours [68] | 2011 | ✓ | 63 | 50 | ✓ |
| The development of evidence-based European guidelines on the management of depression in palliative cancer care [69] | 2011 | 41 | 71 | | |
in which to assess document quality over time. We compared overall differences between journals and between consensus statement or clinical practice guideline using analysis of variance (ANOVA). We also calculated the mean difference in scores between consensus statement and clinical practice guidelines with their corresponding 95% confidence intervals.

For the additional items collected addressing transparency of document development, we calculated the proportion of responses categorized as “Yes”, “No”, and “Not Reported”. We assessed for differences in the journals’ assessments using a chi-square test (or Fisher’s exact test when dealing with small cell counts in summary contingency tables) at a significance level of 5% while stratifying analyses into categories of consensus statement and clinical practice guideline. Finally, we compared overall items responses according to their consensus statement or clinical practice guideline category.

Agreement between reviewers was assessed by a concordance calculator, determining the number of standard deviations between reviewers, over each domain. A ‘high’ discrepancy score occurred when greater than 2 standard deviations were present between reviewers, ‘medium’ if >1.5 but ≤2 standard deviations and ‘low’ if <1.5 standard deviations.

Results

Identified Literature

The search identified a total of 104 documents for review. Three were excluded as one was a physician survey, one was a review of guidelines, and one was a letter to the editor. Therefore, 34 consensus statements and 67 practice guidelines were retained for assessment. The numbers and types of documents for each journal were: CO-14 consensus statements, 24 clinical practice guidelines, EJC -9 consensus statements, 13 clinical practice guidelines and JCO-11 consensus statements, 30 clinical practice guidelines.

AGREE II Rigour of development scores

When assessed across all three journals (Figure 1, Table 2), the mean scores for consensus statements were 32% (95% CI 27–38%) and for clinical practice guidelines 64% (95% CI 59–69%). The mean difference between guidelines was 32% (p<0.0001), indicating that clinical practice guidelines were scored significantly higher than consensus statements in terms of rigour of development. Analyses stratified by journal showed that rigour of development scores were significantly lower for consensus
Table 6. Journal of Clinical Oncology Consensus Statements and Clinical Practice Guidelines.

| Journal of Clinical Oncology | Consensus Statements | Year published | Pharma sponsored | AGREE Domain 3 | AGREE Domain 6 | Sponsors product endorsed |
|-----------------------------|---------------------|----------------|------------------|----------------|----------------|---------------------------|
| Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. [72] | 2007 | 49 | 63 |
| Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting. [73] | 2007 | 9 | 67 |
| Consensus Report of the National Cancer Institute Clinical Trials Planning Meeting on Pancreas Cancer Treatment [74] | 2009 | 7 | 67 |
| Venous Thromboembolism Prophylaxis and Treatment in Cancer: A Consensus Statement of Major Guidelines Panels and Call to Action [11] | 2009 | 52 | 71 |
| Definition, Prognostic Factors, Treatment, and Response Criteria of Adult T-Cell Leukemia-Lymphoma: A Proposal From an International Consensus Meeting. [75] | 2009 | 38 | 67 |
| International Myeloma Working Group Consensus Statement Regarding the Current Status of Allogeneic Stem-Cell Transplantation for Multiple Myeloma [76] | 2010 | 23 | 46 |
| Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group [77] | 2010 | 29 | 42 |
| Hepatocellular Carcinoma: Consensus Recommendations of the National Cancer Institute Clinical Trials Planning Meeting [78] | 2010 | 35 | 67 |
| Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting. [79] | 2011 | 30 | 67 |

**Consensus Statements pre IOM 2011 (n = 9), Mean (95% Confidence Interval)**

| Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. [80] | 2011 | 8 | 63 |
| Platinum-Induced Ototoxicity in Children: A Consensus Review on Mechanisms, Predisposition, and Protection, Including a New International Society of Pediatric Oncology Boston Ototoxicity Scale. [81] | 2012 | 45 | 79 |

**Consensus Statements post IOM 2011 (n = 29), Mean (95% Confidence Interval)**

| American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer. [82] | 2005 | 75 | 73 |
| Colorectal Cancer Surveillance: 2005 Update of an American Society of Clinical Oncology Practice Guideline [83] | 2005 | 65 | 79 |
| American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. [84] | 2006 | 82 | 65 |
| 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline. [85] | 2006 | 57 | 77 |
| American Society of Clinical Oncology Clinical Practice Guideline for the Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer. [86] | 2006 | 65 | 54 |
| American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006. [87] | 2006 | 65 | 64 |
| American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer. [88] | 2007 | 81 | 63 |
**Table 6.** Cont.

| Consensus Statements | Year published | Pharma sponsored | AGREE Domain 3 | AGREE Domain 6 | Sponsors product endorsed |
|----------------------|----------------|------------------|----------------|----------------|--------------------------|
| Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non–Small-Cell Lung Cancer Guideline [89]. | 2007 | 79 | 88 | | |
| American Society of Clinical Oncology Endorsement of the Cancer Care Ontario Practice Guideline on Nonhormonal Therapy for Men With Metastatic Hormone-Refractory (castration-resistant) Prostate Cancer. [90] | 2007 | 69 | 92 | | |
| American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates in Multiple Myeloma. [91] | 2007 | 60 | 75 | | |
| Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2007 Update of an American Society of Clinical Oncology Practice Guideline. [92] | 2007 | 75 | 38 | | |
| American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiation Therapy Protectants. [93] | 2009 | 70 | 58 | | |
| Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. [94] | 2009 | 76 | 71 | | |
| American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer [95]. | 2009 | 71 | 71 | | |
| American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen,Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction [96]. | 2009 | 74 | 63 | | |
| American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update on the Use of Epoetin and Darbepoetin in Adult Patients With Cancer [97]. | 2010 | 57 | 54 | | |
| American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer [98]. | 2010 | 54 | 54 | | |
| American Society of Clinical Oncology Clinical Practice Guideline on Uses of Serum Tumor Markers in Adult Males With Germ Cell Tumors [99]. | 2010 | 58 | 63 | | |
| American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer [100]. | 2010 | 65 | 47 | | |
| **Clinical Practice Guidelines pre IOM 2011 (n = 19) Mean (95% Confidence Interval)** | | | | | |
| Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update [101]. | 2011 | 72 | 67 | | |
| American Society of Clinical Oncology Endorsement of the Cancer Care Ontario Practice Guideline on Adjuvant Ovarian Ablation in the Treatment of Premenopausal Women With Early-Stage Invasive Breast Cancer [102]. | 2011 | 85 | 79 | | |
| 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer [103]. | 2011 | 43 | 58 | | |
| American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Chemotherapy Sensitivity and Resistance Assays [104]. | 2011 | 54 | 58 | | |
| Sentinel Lymph Node Biopsy for Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Joint Clinical Practice Guideline [105]. | 2012 | 63 | 75 | | |
statements than clinical practice guidelines for manuscripts published in CO (31% [95% CI 21–40%] consensus statements, 70% [95% CI 61–79%] clinical practice guidelines) and JCO (30% [95% CI 19–41%] consensus statements, 68% [95% CI 64–72%] clinical practice guidelines). There was no significant difference between manuscripts published in EJC (36% [95% CI 28–45%] consensus statements, 46% [95% CI 32–60%] clinical practice guidelines). When comparing each journal with the others, all three had similar scores for consensus statements; however EJC clinical practice guidelines scored lower than Current Oncology (EJC 46% [95% CI 32–60%], CO 70% [95% CI 61–79%]) and JCO (68% [95% CI 64–72%]). Discrepancy levels between the reviewers were low for all documents.

**AGREE II Editorial independence scores**

When assessed across all three journals (Figure 2, Table 2), the mean score for consensus statements was 53% (95% CI 47–59%) and for clinical practice guidelines was 68% (95% CI 63–73%). The mean difference between consensus statement and clinical practice guideline scores was 15% (p = 0.0009), indicating that clinical practice guidelines were scored significantly higher than consensus statements with respect to editorial independence. Editorial independence scores were significantly lower for consensus statements than clinical practice guidelines in documents published in CO (30% [95% CI 22–42%] consensus statements, 73% [95% CI 65–80%] clinical practice guidelines). This difference seen to a lesser extent in EJC (44% [95% CI 34–54%] consensus statements, 59% [95% CI 52–67%] clinical practice guidelines) and no difference was seen in JCO (63% [95% CI 56–70%] consensus statements, 66% [95% CI 61–70%] clinical practice guidelines). EJC (44% [95% CI 35–54%]) scored lower than JCO (63% [95% CI 56–70%]) on consensus statements, but similarly to CO. No journal appeared to perform better or worse than the other journals with regard to clinical practice guidelines. Discrepancy levels between the reviewers were low for all documents.

**Additional transparency of document development item scores**

Consensus statements infrequently referenced or conducted a systematic review on the topic of the guideline (6/34 = 18%), a step which was much more common with clinical practice guidelines (56/67 = 83%) (p = 0.018) (Table 3). The largest discrepancy was seen in JCO where 0/11 (0%) of consensus statements documented a systematic review compared to 28/30 (93%) of clinical practice guidelines. Neither consensus statements (50%) nor clinical practice guidelines (34%) consistently declared how their development group was established. Consensus statements were more likely than clinical practice guidelines to state that participants were “invited” (12/34 = 35% vs 14/67 = 21%; p = 0.01). Guideline groups were multidisciplinary in 21 out of 34 (62%) consensus statements and 50 out of 67 (75%) clinical practice guidelines groups. Group member roles were not declared in 35% (12/34) of the consensus statements nor in 25% (17/67) of clinical practice guidelines (p = 0.19).

While consensus statements were more likely to declare private funding (11/34 = 32%) than clinical practice guidelines (6/67 = 9%) (p<0.0001), many documents did not declare their source of funding (22/34 = 63% of consensus statements versus 31/67 = 46% of clinical practice guidelines). If a source of funding was declared, the funding body was recorded (Table 3).

With respect to whether or not a document endorsed a product made by the sponsoring company (Table 3), this occurred less frequently in clinical practice guidelines (2/67 = 3%) than in consensus statements (10/34 = 29%) (p<0.0001). In CO, consensus statements endorsed the product of the sponsoring company in
9/14 (64%) of cases. All of these documents declared financial support from the sponsoring company, but none explicitly declared the link between the sponsoring company and the product endorsed. Four percent of clinical practice guidelines published in CO endorsed the sponsor’s product. This trend was seen to a lesser extent in EJC with 11% of consensus statements endorsing sponsors products and 8% of clinical practice guidelines. No document published by JCO documented a relationship between pharmaceutical company funding and product endorsement in the guideline.

Discussion

As the terms consensus statement and clinical practice guidelines are often used interchangeably and both are used to improve clinical care, their methodological rigour and transparency of development is essential. Here we report the results of a review of the methodological quality of consensus statements and clinical practice guidelines in a limited sample of the oncology literature. While others have published on quality assessment of clinical guidelines in oncology using either the AGREE or AGREE II tool [112-117], to our knowledge this is the first such comprehensive review of both consensus statement and practice guidelines in oncology.

As literature assessing the quality of consensus statements is limited [118], we used tools developed for clinical practice guidelines and collected additional information that would help assess the transparency of guideline development. AGREE II is a validated appraisal tool for assessing the methodological development quality and reporting of practice guidelines; it does not assess the actual content of clinical recommendations [5]. AGREE II assesses how well a guideline performs on each of the 6 domains (scope and purpose, stakeholder involvement, rigour of development, clarity of presentation, applicability and editorial independence). We felt the rigour of development (an assessment of the evidentiary base and methods used to formulate recommendations) and editorial independence (an assessment of bias and competing interests influencing recommendation formulation [5]) were the most appropriate for our evaluation.

For both the rigour of development and editorial independence domains, consensus statements scored consistently less well than did practice guidelines. In the only publication we found evaluating practice guidelines in comparison to consensus statements, although not specific to oncology [118], similar differences were seen, with consensus statements scoring significantly lower than clinical practice guidelines across 4 of the 6 AGREE II domains (stakeholder involvement, rigour of development, clarity, and presentation and applicability). We could show no improvement in document quality over time.

Performing a systematic review is an essential element of guideline development [119]. Both IOM [120] and JCO [10] state that “clinical practice guideline developers should use systematic reviews” and that “guidelines/recommendations should be driven by a high level of evidence” respectively. We felt it was necessary to specifically ask ‘was a systematic review performed?’ We asked this question even though AGREE II domain 3.1 assess if ‘systematic methods were used to search for evidence’ (scored on a continuum of whether a guideline reports what databases were searched, the search terms used, the search time periods and the inclusion of a full search strategy). In the current study systematic reviews were performed more frequently by clinical practice guidelines than consensus statements across all three journals. With respect to the processes by which a clinical practice guideline group was established and the role of individual members, this was inconsistently reported. There were however significant differences between these items in consensus statements and clinical practice guidelines.

Of particular interest was the role of the funding body for the development of the guidance document. While no information can be gleaned for whether this association is real or implied, several observations can be made. Overall, consensus statements and clinical practice guidelines published in the three journals studied either did not declare or were not explicit about the funding source for the document (funding source not declared in 65% consensus statements, 45% clinical practice guidelines). For documents with topics related to pharmaceutical products, when the document was sponsored by a pharmaceutical company, documents endorsed the sponsor’s product in both consensus statements (29%) and to a lesser degree in clinical practice guidelines (3%). However, in the CO journal, 64% of consensus statements published endorsed the sponsors product, whereas only 4% of clinical practice guidelines endorsed the sponsors product. Further, this association was not reported in the conflict of interest statement. This absence of reporting contravenes standards published by medical societies [121,122] and could question the integrity and quality of published guidance documents [123,124].

We acknowledge a number of study limitations. Although we feel that consensus statements should be subjected to the same rigorous criteria for their development as practice guidelines, the AGREE II tool has not been validated for evaluation of consensus statements [5,118]. The additional items we included for assessment from the IOM guideline standards and JCO authorship guidance on consensus statements and clinical practice guidelines also have not been validated. Consensus statements and clinical practice guidelines analyzed here may not be representative of all oncology consensus statements and clinical practice guidelines released between January 2005 and September 2013, nor representative of all oncology journals. A brief PubMed search suggests over 900 oncology guidance documents were published in peer-reviewed journals over the same time period, translating to a sample of 11% of these documents. Finally, we chose only three journals from which to sample. Our rational for selecting them was that they commonly publish both consensus statements and clinical practice guidelines, are prominent journals in their locale of origin and are geographically diverse. We appreciate that these journals may not be representative of all oncology journals.

Conclusions

While consensus statements and clinical practice guidelines are developed with slightly different approaches and methods, both are used to inform clinical and policy decisions. As such both documents should be developed using equally rigorous and transparent methods and subjected to high quality standards. Here we have shown that consensus statements score lower than clinical practice guidelines for scores of rigour of development and editorial independence. Consensus statements are also less likely to include a systematic review of the literature and were more likely
to be sponsored by a pharmaceutical company and to endorse a specific pharmaceutical product. Unfortunately transparency of document development was generally poor in both types of documents and there was infrequent documentation of sources of funding, how guideline groups were established and who considered their guideline development.

Given the important role of guidance we feel that both consensus statements and clinical practice guidelines should be subject to the same rigorous and high quality development criteria. We suggest that journals encourage authors of guidance documents to use the AGREE II and IOM criteria when developing their documents and require journal reviewers to use these same criteria when undertaking their peer-review of these documents. While there are quality differences between each of the journals sampled in our study, this was most pronounced around the issues of private funding and product endorsement. Readers of guidance documents published within these journals should be made aware of the presence of private funding and sponsorship should be made transparent through their reporting so that readers can acknowledge such conflicts and potential bias.

**Acknowledgments**

We would like to acknowledge Chika Agbassi, Fulvia Baldassarre, Judy Brown, Nadia Coakley, Karen Spithoff, and Caroline Zwaal for their assistance in data collection.

**Author Contributions**

Conceived and designed the experiments: CJ IG DF M. Clemens BH. Performed the experiments: CJ JM M. Chasse BH M. Clemens. Analyzed the data: CJ JM M. Chasse BH M. Clemens. Contributed reagents/materials/analysis tools: CJ JM M. Chasse BH M. Clemens. Contributed to the writing of the manuscript: CJ JM M. Chasse BF BH M. Clemens.

**References**

1. Woolf SH, Greul R, Hutchinson A, Eccles M, Grimshaw J (1999) Potential conflicts of interest in the writing of clinical guidelines. BMJ 318: 327–330.
2. Grimshaw JM, Russell IT (1993) Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet 342: 1317–1322.
3. Graham MM, Miller Womlan D, Greenfield S, Steinberg E, Editors. Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. Clinical Practice Guidelines Clinical Practice Guidelines We Can Trust. Institute of Medicine. 4. (2009) Mosby's Medical Dictionary. 8th Edition ed. Elsevier.
5. Brouwers MC, Klie ME, Brouwman GP, Burgers JS, Chauveau F, et al. (2010) AGREE II: advancing guidance development, reporting and evaluation in health care. Cmaj 182: E599–E602.
6. Guidelines International Network. Available: http://www.g-i-n.net/. Accessed 25 May 2014.
7. Canadian partnership against cancer and pCODR. (2013) How cancer drug funding decisions are made Available: http://www.pcodr.ca/idc/groups/pcodr/documents/pcodrfund/pcodrfunding-fundamental. Accessed 28 April 2014.
8. Brouwers (2010) Standards and Guidelines Evidence (SAGE) Directory of Canadian Guidelines. Available: http://www.cancerview.ca/cv/piter/Home/TreatmentAndSupport/TSProfessionals/ClinicalGuidelines/GRCMain/GRCSAGE2_addfLoop=176960541900038dk%26_afWindowMode=0%26_addfጛtate=infom%2ftx_35. Accessed 28 September 2013.
9. Brouwers MC, Rawski E, Spithoff K, Oliver TK (2011) Dictionary of Cancer Guidelines: a tool to advance the guideline enterprise and improve the uptake of evidence. Expert Rev Pharmacoecon Outcomes Res 11: 151–161.
10. Oncology GI Information for Contributors.
11. Khourana AA, Streif MB, Farge D, Mandala M, Debourdeau P, et al. (2009) Venous Thromboembolism Prophylaxis and Treatment in Cancer: A Consensus Statement of Major Guidelines Panels and Call to Action. Journal of Clinical Oncology 27: 4919–4926.
12. Lecureulle P, Bout MJ, Belanger R, Couban S, Forrest DL, et al. (2006) Recommendations of the canadian consensus group on the management of chronic myeloid leukemia. Curr Oncol 13: 201–222.
13. Hanna W, O'Malley F, Barnes P, Beredhi B, Gaboury L, et al. (2007) Updated recommendations from the Canadian National Consensus Meeting on HER2/neu testing in breast cancer. Curr Oncol 14: 149–153.
14. Colorectal Cancer Association of Canada consensus meeting: raising the standards of care for early-stage rectal cancer (2009) Curr Oncol 16: 50–56.
15. Ellis PM, Morecki W, Melosky B, Butts C, Hirsh V, et al. (2009) The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent non-small-cell lung cancer: a Canadian national consensus statement. Curr Oncol 16: 27–48.
16. Cripps C, Gill S, Ahmed S, Colwell B, Dowden S, et al. (2010) Consensus recommendations for the use of anti-egr therapies in metastatic colorectal cancer. Curr Oncol 17: 39–45.
17. Vickers M, Samson B, Colwell B, Cripps C, Jalak D, et al. (2010) Eastern Canadian Colorectal Cancer Consensus Conference: setting the limits of resectable disease. Curr Oncol 17: 70–77.
18. Koch W, Maroun J, Kneenke H, Law C, Metrakos P, et al. (2010) Consensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuroendocrine tumours: a revised statement from a Canadian National Expert Group. Curr Oncol 17: 49–64.
19. Amin T, Baha F, Scully L, Papadatos D, Margueau C, et al. (2010) Diagnosis and management of hepatocellular carcinoma: results of a consensus meeting of The Ottawa Hospital Cancer Centre. Curr Oncol 17: 6–12.
20. Sherman M, Burak K, Maroun J, Metrakos P, Knox J, et al. (2011) Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. Curr Oncol 18: 228–240.
21. Aubin F, Gill S, Burkes R, Colwell B, Kannel-Reid S, et al. (2011) Canadian Expert Group Consensus Recommendations: K-RAS testing in colorectal cancer. Curr Oncol 18: e180–e184.
22. Vickers MM, Pasieka J, Dixon E, McEwan S, McKay A, et al. (2012) Report from the 13th annual Western Canadian gastrointestinal cancer consensus conference: calgary, alberta; september 8–10, 2011. Curr Oncol 19: e60–e77.
23. McEwen S, Egan M, Chasen M, Fitzh M (2013) Consensus recommendations for cancer rehabilitation: research and education priorities. Curr Oncol 20: 64–69.
24. Mitchell Ki, Gelmon KA, Rayson D, Provencher L, Webster M, et al. (2013) Endocrine therapy for postmenopausal women with hormone receptor-positive hr2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statement. Curr Oncol 20: 48–61.
25. Di Valentin T, Biagi J, Bourque S, Butt R, Champion P, et al. (2013) Eastern Canadian Colorectal Cancer Consensus Conference: standards of care for the treatment of patients with rectal, pancreatic, and gastrointestinal stromal tumours and pancreatic neuroendocrine tumours. Curr Oncol 20: e453–e464.
26. Reece D, Imrie K, Stewen A, Smith CA (2006) Beotecamiba in multiple myeloma and lymphoma: a systematic review and clinical practice guideline. Curr Oncol 13: 160–172.
27. Maroun J, Kocha W, Kwoh L, Bjarnason G, Chen E, et al. (2006) Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group. Curr Oncol 13: 67–76.
28. Konkel D, Rumble RB, Maroun J (2006) Role of oxaliplatin combined with 5-fluorouracil and folinic acid in the first- and second-line treatment of advanced colorectal cancer. Curr Oncol 13: 173–184.
29. Mason WP, Maestro RD, Eunstate D, Forsyth P, Fulton D, et al. (2007) Canadian recommendations for the treatment of glioblastoma multiforme. Curr Oncol 14: 110–117.
30. Quitt I, Verma S, Petrella T, Bak K, Charette M, et al. (2007) Temozolomide for the Treatment of Metastatic Melanoma: A Practice Guideline. Current Oncology, [S1]14.
31. Verma S, Yousman J, Syx-Norman D, Haynes AE, Blackstein M (2007) Ifosfamide-based combination chemotherapy in advanced soft-tissue sarcoma: a practice guideline. Curr Oncol 14: 144–148.
32. Mintz A, Perry J, Spithoff K, Chambers A, Lapierre N (2007) Management of single brain metastasis: a practice guideline. Curr Oncol 14: 131–143.
33. Fraser GSC, Imrie K, Meyer R (2007) Alentuzumab in Chronic Lymphocytic Leukemia: A Systematic Review and Clinical Practice Guideline. Current Oncology, [S1]14.
34. Petrella T, Quitt I, Verma S, Haynes AE, Charette M, et al. (2007) Single-Agent Interleukin-2 in the Treatment of Metastatic Melanoma: A Clinical Practice Guideline. Curr Oncol 14: 21–26.
35. Verma S, Petrella T, Hamin C, Bak K, Charette M (2008) Biochemotherapy for the treatment of metastatic malignant melanoma: a clinical practice guideline. Curr Oncol 15: 85–89.
36. Verma S, Yousman J, Haynes AE, Syx-Norman D, Blackstein M (2008) Dose-intensive chemotherapy with growth factor or autologous bone marrow or stem-cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma: a clinical practice guideline. Curr Oncol 15: 80–94.
37. Cripps C, Winquist E, Devries MC, Stys-Norman D, Gilbert R (2010) Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer. Curr Oncol 17: 37–48.
38. Eliot L, Fyles AW, Oliver TK, Devries-Aboud MC, Fung-Kee-Fung M (2010) Follow-up for women after treatment for cervical cancer. Curr Oncol 17: 65–69.
51. Van Cutsem E, Nordlinger B, Adam R, Kohne C-H, Pozzo C, et al. (2006) Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. European journal of cancer (Oxford, England: 1990) 46: 270–263.

52. Gridelli C, Rossi A, Maione P (2010) Clinical Oncology 28: 4976–4984.

53. Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, et al. (2010) Managing Multiple Myeloma: A Consensus Statement of the International Society for Myeloma Biology. Journal of Clinical Oncology 28: 3994–4005.

54. Tsakasaki K, Hermine O, Bazarbachi A, Ramírez L, Ramos JC, et al. (2009) Clinical Oncology 27: 5660–5669.

55. Lokhorst H, Einsele H, Vesole D, Bruno B, Miguel JS, et al. (2010) Lenalidomide in multiple myeloma—A practice guideline. Curr Oncol 20: e110469.

56. Lutz MP, Zaldberg JR, Ducreux M, Ajanja MA, Allum W, et al. (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer 48: 599–641.

57. Gupta AA, Yao X, Verma S, Mackay H, Hopkins L (2013) Chemotherapy of early (T1) glottic cancer: a clinical practice guideline. Curr Oncol 19: e244–257.

58. Gallinger S, Biagi JJ, Fletcher GG, Nhan C, Ruo L, et al. (2013) Liver resection of early hepatocellular carcinoma: a pan-Canadian practice guideline. Curr Oncol 20: e304–310.

59. Czauderna P, Otte JB, Aronson DC, Gauthier F, Mackinlay G, et al. (2005) EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. European journal of cancer (Oxford, England: 1990) 42: 2212–2223.

60. Gridelli C, Rossi A, Maione P (2010) Clinical Oncology 28: 4976–4984.

61. Catalassi L, De Wolf C, Holland R, Marotti L, Perry N, et al. (2007) Guidelines on the standards for the training of specialised health professionals dealing with breast cancer. Eur J Cancer 43: 660–675.

62. Quinn B, Potting CM, Stone R, Blijlevens NM, Fledder M, et al. (2008) Guidelines for the assessment of oral mucositis in adult chemotherapy, radiotherapy and haematopoietic stem cell transplant patients. Eur J Cancer 44: 61–72.

63. Aspripolitis, Valerio B, Bucchieri F, Correly OA, Kelmise M, et al. (2009) Diagnosis and antimicrobial therapy of fung infection in febrile neutropenic patients: Guidelines of the infectious diseases working party of the German Society of Haematology and Oncology. Eur J Cancer 45: 2462–2472.

64. Gridelli C, Rossi A, Maione P (2010) 2010 Consensus on Lung Cancer, new clinical recommendations. European journal of cancer (Oxford, England: 1990) 46: 3168–3171.

65. Feunteun J, Tournade MF, Ludden RB, Gaulard P, et al. (2006) A Consensus Report on the National Cancer Institute Clinical Trials Planning Meeting on Pancreas Cancer Treatment. Journal of Clinical Oncology 24: 5660–5669.

66. Thomas MB, Jaffe D, Chiou MM, Belghiti J, Curley S, et al. (2010) Intestinal Myeloma Working Group: consensus management regarding the current Status of Allogeneic Stem-Cell Transplantation for Multiple Myeloma. Journal of Clinical Oncology 28: 4521–4530.

67. Tsakasaki K, Hermine O, Bazarbachi A, Ramírez L, Ramos JC, et al. (2009) Consensus Report of the National Cancer Institute Cancer Trials Planning Meeting. Journal of Clinical Oncology 27: 453–459.

68. Lokhorst H, Einsele H, Vesole D, Bruno B, Miguel JS, et al. (2010) Intestinal Myeloma Working Group: consensus management regarding the current Status of Allogeneic Stem-Cell Transplantation for Multiple Myeloma. Journal of Clinical Oncology 28: 4521–4530.

69. Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, et al. (2011) Future Directions in the Treatment of Neuroendocrine Tumours: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting. Journal of Clinical Oncology 29: 934–943.

70. Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, et al. (2011) Clinical Practice Guidelines and Consensus Statements in Oncology. Clinical Practice Guidelines and Consensus Statements in Oncology.

71. Tsakasaki K, Hermine O, Bazarbachi A, Ramírez L, Ramos JC, et al. (2009) Consensus Report on the National Cancer Institute Clinical Trials Planning Meeting on Pancreas Cancer Treatment. Journal of Clinical Oncology 27: 5660–5669.

72._lokhst H, Einsele H, Vesole D, Bruno B, Miguel JS, et al. (2010) Intestinal Myeloma Working Group: consensus management regarding the current Status of Allogeneic Stem-Cell Transplantation for Multiple Myeloma. Journal of Clinical Oncology 28: 4521–4530.

73. Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, et al. (2011) Future Directions in the Treatment of Neuroendocrine Tumours: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting. Journal of Clinical Oncology 29: 934–943.

74. Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, et al. (2011) Clinical Practice Guidelines and Consensus Statements in Oncology. Clinical Practice Guidelines and Consensus Statements in Oncology.

75. Tsakasaki K, Hermine O, Bazarbachi A, Ramírez L, Ramos JC, et al. (2009) Consensus Report of the National Cancer Institute Cancer Trials Planning Meeting. Journal of Clinical Oncology 27: 453–459.

76. Lokhorst H, Einsele H, Vesole D, Bruno B, Miguel JS, et al. (2010) Intestinal Myeloma Working Group: consensus management regarding the current Status of Allogeneic Stem-Cell Transplantation for Multiple Myeloma. Journal of Clinical Oncology 28: 4521–4530.
